Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Published in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie 6/2022

23-03-2022 | Myasthenia Gravis | Review Article/Brief Review

Mapping the current evidence on the anesthetic management of adult patients with neuromuscular disorders—a scoping review

Authors: Luuk R. van den Bersselaar, MD, Madelief Gubbels, BSc, Sheila Riazi, MD, Luc Heytens, MD, PhD, Heinz Jungbluth, MD, PhD, Nicol C. Voermans, MD, PhD, Marc M. J. Snoeck, MD, PhD

Published in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Issue 6/2022

Login to get access

Abstract

Purpose

Patients with neuromuscular disorders (NMDs) are at increased risk of perioperative complications. The objective of this scoping review was to examine emerging evidence from published studies, case reports, and review articles on anesthetic management of patients with NMDs, following the methodological frame for scoping reviews.

Sources

We searched PubMed and EMBASE for articles published between 1 January 2000 and 14 July 2021.

Principal findings

Three prospective and 21 retrospective studies on altered pharmacokinetics and pharmacodynamics of neuromuscular blocking agents (NMBA) in NMD patients were included. Furthermore, 168 case reports/series reporting 212 anesthetics in 197 patients were included. These studies showed that preanesthetic neuromuscular monitoring can be used for precise NMBA dosing in myasthenia gravis patients. Sugammadex was associated with fewer postoperative myasthenic crises. Perioperative complications were not associated with specific anesthetic agents. Case reports/series showed that in 32% (67/212) of anesthetics, at least one complication was reported. Unexpected intensive care unit admission was a frequently reported complication. Patients with a complicated disease course may have had a higher use of succinylcholine (unadjusted relative risk, 0.13; 95% confidence interval [CI], 0.20 to 0.86) and volatile anesthetics (adjusted odds ratio [OR], 0.38; 95% CI, 0.20 to 0.73; P = 0.004).

Conclusion

Evidence on the anesthetic management and perioperative complications of patients with NMDs is mainly based on small retrospective studies and case reports. Further clinical trials or large retrospective studies are required to investigate the choice of safe anesthetic agents. Main areas of interest are the potential benefits of neuromuscular monitoring and sugammadex and the risks possibly associated with volatile anesthetics and succinylcholine.
Appendix
Available only for authorised users
Literature
1.
2.
Benarroch L, Bonne G, Rivier F, Hamroun D. The 2020 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord 2019; 29: 980-1018.PubMedCrossRef
3.
Bhakta D, Lowe MR, Groh WJ. Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I. Am Heart J 2004; 147: 224-7.PubMedCrossRef
4.
Posner AD, Soslow JH, Burnette WB, et al. The correlation of skeletal and cardiac muscle dysfunction in duchenne muscular dystrophy. J Neuromuscul Dis 2016; 3: 91-9.PubMedPubMedCentralCrossRef
5.
DePalo VA, McCool FD. Respiratory muscle evaluation of the patient with neuromuscular disease. Semin Respir Crit Care Med 2002; 23: 201-9.PubMedCrossRef
6.
Silvestri NJ, Ismail H, Zimetbaum P, Raynor EM. Cardiac involvement in the muscular dystrophies. Muscle Nerve 2018; 57: 707-15.PubMedCrossRef
7.
Litman RS, Griggs SM, Dowling JJ, Riazi S. Malignant hyperthermia susceptibility and related diseases. Anesthesiology 2018; 128: 159-67.PubMedCrossRef
8.
Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology 2006; 104: 158-69.PubMedCrossRef
9.
Fischer U, Reinhardt S, Albuquerque EX, Maelicke A. Expression of functional alpha7 nicotinic acetylcholine receptor during mammalian muscle development and denervation. Eur J Neurosci 1999; 11: 2856-64.PubMedCrossRef
10.
Klingler W, Lehmann-Horn F, Jurkat-Rott K. Complications of anaesthesia in neuromuscular disorders. Neuromuscul Disord 2005; 15: 195-206.PubMedCrossRef
11.
Schieren M, Defosse J, Böhmer A, Wappler F, Gerbershagen MU. Anaesthetic management of patients with myopathies. Eur J Anaesthesiol 2017; 34: 641-9.PubMedCrossRef
12.
Katz JA, Murphy GS. Anesthetic consideration for neuromuscular diseases. Curr Opin Anaesthesiol 2017; 30: 435-40.PubMedCrossRef
13.
14.
van den Bersselaar LR, Riazi S, Snoeck M, Jungbluth H, Voermans NC; Anaesthesia and Neuromuscular Disorders Working Group. 259th ENMC international workshop: anaesthesia and neuromuscular disorders 11 December, 2020 and 28-29 May, 2021. Neuromuscul Disord 2021. https://​doi.​org/​10.​1016/​j.​nmd.​2021.​11.​005.
15.
16.
Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018; 169: 467-73.PubMedCrossRef
17.
Lockwood C, Dos Santos KB, Pap R. Practical guidance for knowledge synthesis: scoping review methods. Asian Nurs Res (Korean Soc Nurs Sci) 2019; 13: 287-94.
18.
Mann R, Blobner M, Jelen-Esselborn S, Busley R, Werner C. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients. Anesthesiology 2000; 93: 346-50.PubMedCrossRef
19.
Fujimoto M, Terasaki S, Nishi M, Yamamoto T. Response to rocuronium and its determinants in patients with myasthenia gravis: a case-control study. Eur J Anaesthesiol 2015; 32: 672-80.PubMedCrossRef
20.
Caron MJ, Girard F, Girard DC, et al. Cisatracurium pharmacodynamics in patients with oculopharyngeal muscular dystrophy. Anesth Analg 2005; 100: 393-7.PubMedCrossRef
21.
Alshaikh JT, Amdur R, Sidawy A, Trachiotis G, Kaminski HJ. Thymectomy is safe for myasthenia gravis patients: analysis of the NSQIP database. Muscle Nerve 2016; 53: 370-4.PubMedCrossRef
22.
Ando T, Omasa M, Kondo T, et al. Predictive factors of myasthenic crisis after extended thymectomy for patients with myasthenia gravis. Eur J Cardiothorac Surg 2015; 48: 705-9.PubMedCrossRef
23.
Fujita Y, Moriyama S, Aoki S, et al. Estimation of the success rate of anesthetic management for thymectomy in patients with myasthenia gravis treated without muscle relaxants: a retrospective observational cohort study. J Anesth 2015; 29: 794-7.PubMedCrossRef
24.
Kas J, Kiss D, Simon V, Svastics E, Major L, Szobor A. Decade-long experience with surgical therapy of myasthenia gravis: early complications of 324 transsternal thymectomies. Ann Thorac Surg 2001; 72: 1691-7.PubMedCrossRef
25.
Lu W, Yu T, Longhini F, Jiang X, Qin X, Jin X. Preoperative risk factors for prolonged postoperative ventilation following thymectomy in myasthenia gravis. Int J Clin Exp Med 2015; 8: 13990-6.PubMedPubMedCentral
26.
Mouri H, Jo T, Matsui H, Fushimi K, Yasunaga H. Effect of sugammadex on postoperative myasthenic crisis in myasthenia gravis patients: propensity score analysis of a Japanese nationwide database. Anesth Analg 2020; 130: 367-73.PubMedCrossRef
27.
Saylan S, Akdogan A. Anesthesia and neuromuscular block management in thymectomies performed in cases of thymoma and myasthenia gravis: a retrospective study. J Clin Anal Med 2021; 12: 327-31.
28.
Vymazal T, Krecmerova M, Bicek V, Lischke R. Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery - a series of 117 cases. Ther Clin Risk Manag 2015; 11: 1593-6.PubMedPubMedCentralCrossRef
29.
Imison AR. Anaesthesia and myotonia--an Australian experience. Anaesth Intensive Care 2001; 29: 34-7.PubMedCrossRef
30.
31.
Kirzinger L, Schmidt A, Kornblum C, Schneider-Gold C, Kress W, Schoser B. Side effects of anesthesia in DM2 as compared to DM1: a comparative retrospective study. Eur J Neurol 2010; 17: 842-5.PubMedCrossRef
32.
Weingarten TN, Hofer RE, Milone M, Sprung J. Anesthesia and myotonic dystrophy type 2: a case series. Can J Anesth 2010; 57: 248-55.PubMedCrossRef
33.
Hoeper AM, Barbara DW, Watson JC, Sprung J, Weingarten TN. Amyotrophic lateral sclerosis and anesthesia: a case series and review of the literature. J Anesth 2019; 33: 257-65.PubMedCrossRef
34.
Onders RP, Carlin AM, Elmo M, Sivashankaran S, Katirji B, Schilz R. Amyotrophic lateral sclerosis: the Midwestern surgical experience with the diaphragm pacing stimulation system shows that general anesthesia can be safely performed. Am J Surg 2009; 197: 386-90.PubMedCrossRef
35.
Liu S, Liu Z, Zhang J, et al. Anesthetic strategy for percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis patients. Int J Clin Exp Med 2017; 10: 3725-30.
36.
Boivin A, Antonelli R, Sethna NF. Perioperative management of gastrostomy tube placement in Duchenne muscular dystrophy adolescent and young adult patients: a role for a perioperative surgical home. Paediatr Anaesth 2018; 28: 127-33.PubMedCrossRef
37.
38.
Mortenson AR, Sprung J, Cavalcante AN, Watson JC, Weingarten TN. Inclusion body myositis and anesthesia: a case series. J Clin Anesth 2016; 31: 282-7.PubMedCrossRef
39.
Weingarten TN, Araka CN, Mogensen ME, et al. Lambert-Eaton myasthenic syndrome during anesthesia: a report of 37 patients. J Clin Anesth 2014; 26: 648-53.PubMedCrossRef
40.
Gurrieri C, Kivela JE, Bojanić K, et al. Anesthetic considerations in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome: a case series. Can J Anesth 2011; 58: 751-63.PubMedCrossRef
41.
Pellerin HG, Nicole PC, Trépanier CA, Lessard MR. Postoperative complications in patients with oculopharyngeal muscular dystrophy: a retrospective study. Can J Anesth 2007; 54: 361-5.PubMedCrossRef
42.
43.
Beecroft C, Hough M. Perioperative management of patients with musculoskeletal disease and for the burns patient. Surgery 2016; 34: 405-10.
44.
Hudson KA, Greene JG. Perioperative consultation for patients with preexisting neurologic disorders. Semin Neurol 2015; 35: 690-8.PubMedCrossRef
45.
Muckler VC, O’Brien JM, Matson SE, Rice AN. Perianesthetic implications and considerations for myasthenia gravis. J Perianesth Nurs 2019; 34: 4-15.PubMedCrossRef
46.
Sungur Z, Sentürk M. Anaesthesia for thymectomy in adult and juvenile myasthenic patients. Curr Opin Anaesthesiol 2016; 29: 14-9.PubMedCrossRef
47.
Spasojevic I, Hajdukovic D, Komarcevic M, Petrovic S, Jovanovic J, Ciric A. Specific features of anesthesia in patients with myasthenia gravis. Med Pregl 2016; 69: 305-11.PubMedCrossRef
48.
Collins S, Roberts H, Hewer I. Anesthesia and perioperative considerations for patients with myasthenia gravis. AANA J 2020; 88: 485-91.PubMed
49.
Hoppe K, Pulnien R, Lehman-Horn F, Jurkat-Rott K, Gösele M, Klingler W. Mitochondrial disorders. Anästh Intensivmed 2017; 58: S125-33.
50.
51.
Echeverry-Marín PC, Bustamante-Vega AM. Anesthetic implications of muscular dystrophies. Colombian Journal of Anestesiology 2018; 46: 228-39.CrossRef
52.
Ashizawa T, Gagnon C, Groh WJ, et al. Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurol Clin Pract 2018; 8: 507-20.PubMedPubMedCentralCrossRef
53.
Hoppe K, Jurkatt-Rot K, Lehmann-Horn F, Klingler W. Anaesthesia recommendations for patients suffering from myotonic dystrophies type 1 and 2. Anästh Intensivmed 2015; 56: S667-74.
54.
Álvarez AL, Fernandes AR. Anesthesia recommendations for patients suffering from limb-girdle muscular dystrophy. Anästh Intensivmed 2016; 57: S583-9.
55.
56.
Stourac P, Kosinova M. Anaesthesia recommendations for recessive myotonia congenita (Becker’s disease). Anästh Intensivmed 2019; 60: S545-53.
57.
Jimenez N, Liston DE. Anaesthesia recommendations for patients suffering from merosin-deficient congenital muscular dystrophy. Anästh Intensivmed 2015; 56: S525-31.
58.
Prottengeier J, Shammas K, Smith J. Anaesthesia recommendations for collagen VI-related myopathy. Anästh Intensivmed 2020; 61: S20-6.
59.
Schaller SJ, Lewald H. Clinical pharmacology and efficacy of sugammadex in the reversal of neuromuscular blockade. Expert Opin Drug Metab Toxicol 2016; 12: 1097-108.PubMedCrossRef
60.
Parikh S, Goldstein A, Koenig MK, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med 2015; 17: 689-701.PubMedCrossRef
61.
Broman M, Islander G, Müller CR. Malignant hyperthermia, a Scandinavian update. Acta Anaesthesiol Scand 2015; 59: 951-61.PubMedCrossRef
62.
Riazi S, Kraeva N, Hopkins PM. Malignant hyperthermia in the post-genomics era: new perspectives on an old concept. Anesthesiology 2018; 128: 168-80.PubMedCrossRef
63.
64.
Sangkuhl K, Dirksen RT, Alvarellos ML, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for CACNA1S. Pharmacogenet Genomics 2020; 30: 34-44.PubMedPubMedCentralCrossRef
65.
Carvalho H, Verdonck M, Cools W, Geerts L, Forget P, Poelaert J. Forty years of neuromuscular monitoring and postoperative residual curarisation: a meta-analysis and evaluation of confidence in network meta-analysis. Br J Anaesth 2020; 125: 466-82.PubMedCrossRef
66.
67.
Sugi Y, Nitahara K, Shiroshita T, Higa K. Restoration of train-of-four ratio with neostigmine after insufficient recovery with sugammadex in a patient with myasthenia gravis. A A Case Rep 2013; 1: 43-5.PubMedCrossRef
68.
Kheterpal S, Vaughn MT, Dubovoy TZ, et al. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (STRONGER): a multicenter matched cohort analysis. Anesthesiology 2020; 132: 1371-81.PubMedCrossRef
69.
Kleopa KA, Rosenberg H, Heiman-Patterson T. Malignant hyperthermia-like episode in Becker muscular dystrophy. Anesthesiology 2000; 93: 1535-7.PubMedCrossRef
70.
Gurnaney H, Brown A, Litman RS. Malignant hyperthermia and muscular dystrophies. Anesth Analg 2009; 109: 1043-8.PubMedCrossRef
71.
Breuer T, Maes K, Rossaint R, et al. Sevoflurane exposure prevents diaphragmatic oxidative stress during mechanical ventilation but reduces force and affects protein metabolism even during spontaneous breathing in a rat model. Anesth Analg 2015; 121: 73-80.PubMedCrossRef
72.
Ide T, Kochi T, Isono S, Mizuguchi T. Effect of sevoflurane on diaphragmatic contractility in dogs. Anesth Analg 1992; 74: 739-46.PubMedCrossRef
73.
Ye L, Zuo Y, Zhang P, Yang P. Sevoflurane enhances neuromuscular blockade by increasing the sensitivity of skeletal muscle to neuromuscular blockers. Int J Physiol Pathophysiol Pharmacol 2015; 7: 172-7.PubMedPubMedCentral
74.
Woloszczuk-Gebicka B, Wyska E, Grabowski T. Sevoflurane increases fade of neuromuscular response to TOF stimulation following rocuronium administration in children. A PK/PD analysis. Paediatr Anaesth 2007; 17: 637-46.PubMedCrossRef
75.
Baurain MJ, d’Hollander AA, Melot C, Dernovoi BS, Barvais L. Effects of residual concentrations of isoflurane on the reversal of vecuronium-induced neuromuscular blockade. Anesthesiology 1991; 74: 474-8.PubMedCrossRef
76.
77.
Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth 2019; 122: 448-59.PubMedPubMedCentralCrossRef
78.
De Vries MC, Brown DA, Allen ME, et al. Safety of drug use in patients with a primary mitochondrial disease: an international Delphi-based consensus. J Inherit Metab Dis 2020; 43: 800-18.PubMedPubMedCentralCrossRef
79.
Sambuughin N, Holley H, Muldoon S, et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population. Anesthesiology 2005; 102: 515-21.PubMedCrossRef
80.
Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg 2014; 118: 381-7.PubMedCrossRef
81.
Monnier N, Krivosic-Horber R, Payen JF, et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002; 97: 1067-74.PubMedCrossRef
82.
Weiss RG, O’Connell KM, Flucher BE, Allen PD, Grabner M, Dirksen RT. Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. Am J Physiol Cell Physiol 2004; 287: C1094-102.PubMedCrossRef
83.
Eltit JM, Bannister RA, Moua O, et al. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor. Proc Natl Acad Sci U S A 2012; 109: 7923-8.PubMedPubMedCentralCrossRef
84.
85.
Stamm DS, Aylsworth AS, Stajich JM, et al. Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia. Am J Med Genet A 2008; 146A: 1832-41.PubMedCrossRef
86.
Gray RM. Anesthesia-induced rhabdomyolysis or malignant hyperthermia: is defining the crisis important? Paediatr Anaesth 2017; 27: 490-3.PubMedCrossRef
Metadata
Title
Mapping the current evidence on the anesthetic management of adult patients with neuromuscular disorders—a scoping review
Authors
Luuk R. van den Bersselaar, MD
Madelief Gubbels, BSc
Sheila Riazi, MD
Luc Heytens, MD, PhD
Heinz Jungbluth, MD, PhD
Nicol C. Voermans, MD, PhD
Marc M. J. Snoeck, MD, PhD
Publication date
23-03-2022

Other articles of this Issue 6/2022

Canadian Journal of Anesthesia/Journal canadien d'anesthésie 6/2022 Go to the issue

Correspondence

Continuous wound infusion combined with intrathecal morphine for analgesia after Cesarean delivery compared with intrathecal morphine or continuous wound infusion alone

Correspondence

Airway management in a patient with a traumatic retropharyngeal hematoma causing airway compromise

Correction

Correction to: Airway recommendations for perioperative patients during the COVID-19 pandemic: a scoping review

Correction

Correction: Implementation of the Canadian Cardiovascular Society guidelines for perioperative risk assessment and management: an interrupted time series study

Reports of Original Investigations

Assessment of sensory block during labour epidural analgesia: a prospective cohort study to determine the influence of the direction of testing

Reports of Original Investigations

Factors associated with functional disability or mortality after elective noncardiac surgery: a prospective cohort study